CNS Pharma rises on clearance for brain cancer drug trial in France

CNS Pharmaceuticals

06/04/2022 14:53

** Shares of drug developer  CNSP.O  rise ~4% to $0.39
    ** Says it got approval from France's Competent Authority
and Ethics Committee for a study testing its lead drug
candidate, berubicin, to treat recurrent glioblastoma
multiforme, an aggressive type of brain cancer (https://refini.tv/3J8L8Je)
    ** Company's global trial will involve 243 patients, with
the main goal being overall survival, which measures the length
of time for which patients diagnosed are alive
    ** The drug has received "fast track" and "orphan drug"
designations from U.S. FDA
    ** Stock down ~43.9% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))